Capital International Investors raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 27.8% during the first quarter, HoldingsChannel reports. The firm owned 7,837,074 shares of the company’s stock after buying an additional 1,702,624 shares during the quarter. Capital International Investors owned 0.09% of CRISPR Therapeutics worth $534,175,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of CRSP. Riggs Asset Managment Co. Inc. boosted its holdings in shares of CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after buying an additional 200 shares in the last quarter. Orion Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 44.0% in the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after buying an additional 220 shares in the last quarter. Wealthcare Advisory Partners LLC boosted its holdings in shares of CRISPR Therapeutics by 7.7% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 4,200 shares of the company’s stock valued at $286,000 after buying an additional 300 shares in the last quarter. E Fund Management Co. Ltd. boosted its holdings in shares of CRISPR Therapeutics by 3.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,460 shares of the company’s stock valued at $592,000 after buying an additional 303 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of CRISPR Therapeutics by 55.5% in the 1st quarter. Geneos Wealth Management Inc. now owns 871 shares of the company’s stock valued at $59,000 after buying an additional 311 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Piper Sandler reiterated an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Robert W. Baird raised their target price on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Barclays reduced their target price on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a research note on Thursday, May 9th. Finally, Citigroup reduced their target price on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, May 23rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and an average target price of $75.71.
Insider Buying and Selling at CRISPR Therapeutics
In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by insiders.
CRISPR Therapeutics Trading Up 0.6 %
Shares of CRSP traded up $0.35 during trading hours on Friday, reaching $57.92. The company had a trading volume of 866,898 shares, compared to its average volume of 1,603,022. The firm has a 50 day simple moving average of $57.16 and a 200-day simple moving average of $63.57. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10. The company has a market capitalization of $4.92 billion, a price-to-earnings ratio of -21.29 and a beta of 1.70.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $25.53 million. During the same period in the prior year, the business earned ($0.67) EPS. The company’s quarterly revenue was down 99.5% compared to the same quarter last year. Sell-side analysts forecast that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
See Also
- Five stocks we like better than CRISPR Therapeutics
- Industrial Products Stocks Investing
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- With Risk Tolerance, One Size Does Not Fit All
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- 5 Top Rated Dividend Stocks to Consider
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.